Major depressive disorder is characterized by the presence of at least five of nine specific symptoms that contribute to clinically significant functional impairment. This analysis examined the effect of desvenlafaxine (50 or 100 mg) versus placebo on symptom cluster scores and the association between early improvement in symptom clusters and symptomatic or functional remission at week 8.
Methods:
Using data from nine double-blind, placebo-controlled studies of desvenlafaxine for the treatment of major depressive disorder (N=4317), the effect of desvenlafaxine 50 or 100 mg versus placebo on scores for symptom clusters based on 17-item Hamilton Rating Scale for Depression items was assessed using analysis of covariance. Association between early improvement in symptom clusters (⩾20% improvement from baseline at week 2) and symptomatic and functional remission (17-item Hamilton Rating Scale for Depression total score ⩽7; Sheehan Disability Scale score <7) at week 8 was analyzed using logistic regression. Symptom clusters based on Montgomery–Åsberg Depression Rating Scale were also examined.
Results:
Desvenlafaxine 50 or 100 mg was associated with significant improvement from baseline compared to placebo for all symptom clusters (p<0.001), except a sleep cluster for desvenlafaxine 100 mg. For all symptom clusters, early improvement was significantly associated with achievement of symptomatic and functional remission at week 8 for all treatment groups (p⩽0.0254).
Conclusion:
Early improvement in symptom clusters significantly predicts symptomatic or functional remission at week 8 in patients with depression receiving desvenlafaxine (50 or 100 mg) or placebo. Importantly, patients without early improvement were less likely to remit.
AlbertiSChiesaAAndrisanoC, et al. (2015) Insomnia and somnolence associated with second-generation antidepressants during the treatment of major depression: a meta-analysis. J Clin Psychopharmacol35: 296–303.
2.
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Washington, DC: American Psychiatric Publishing.
3.
American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Publishing.
4.
American Psychiatric Association (2013) Major depressive disorder. In: Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 5th ed.Washington, DC: American Psychiatric Association, 160–168.
5.
ArrollBMacgillivraySOgstonS, et al. (2005) Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med3: 449–456.
6.
BechPGramLFDeinE, et al. (1975) Quantitative rating of depressive states. Acta Psychiatr Scand51: 161–170.
7.
BechPTanghojPAndersenHF, et al. (2002) Citalopram dose–response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology163: 20–25.
8.
BechPTanghojPCialdellaP, et al. (2004) Escitalopram dose–response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Neuropsychopharmacol7: 283–290.
9.
BoyerPMontgomerySLepolaU, et al. (2008) Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol23: 243–253.
10.
CarrascoJLKornsteinSGMcIntyreRS, et al. (2016) An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder. Int Clin Psychopharmacol31: 134–146.
11.
CeladaPPuigMAmargos-BoschM, et al. (2004) The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci29: 252–265.
12.
ChekroudAMGueorguievaRKrumholzHM, et al. (2017) Reevaluating the efficacy and predictability of antidepressant treatments: a symptom clustering approach. JAMA Psychiatry74: 370–378.
13.
CiprianiAFurukawaTASalantiG, et al. (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet391: 1357–1366.
14.
ClaytonATourianKAFochtK, et al. (2015) Desvenlafaxine 50- and 100-mg/d vs placebo for the treatment of major depressive disorder: a Phase 4, randomized controlled trial. J Clin Psychiatry76: 562–529.
15.
ClaytonAHKornsteinSGDunlopBW, et al. (2013) Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry74: 1010–1017.
16.
ClearyPGuyW (1977) Factor analysis of the Hamilton Depression Scale. Drugs Exp Clin Res1: 115–120.
17.
CooperJATuckerVLPapakostasGI (2014) Resolution of sleepiness and fatigue: a comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union. J Psychopharmacol28: 118–124.
18.
DeMartinisNAYeungPPEntsuahR, et al. (2007) A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry68: 677–688.
19.
DunlopBWReddySYangL, et al. (2011) Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol31: 569–576.
20.
FrankEPrienRFJarrettRB, et al. (1991) Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry48: 851–855.
21.
FrazerABenmansourS (2002) Delayed pharmacological effects of antidepressants. Mol Psychiatry7: S23–S28.
GirardiPPompiliMInnamoratiM, et al. (2009) Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods. Hum Psychopharmacol24: 177–190.
24.
GorwoodPBayleFVaivaG, et al. (2013) Is it worth assessing progress as early as week 2 to adapt antidepressive treatment strategy? Results from a study on agomelatine and a global meta-analysis. Eur Psychiatry28: 362–371.
25.
HabertJKatzmanMAOlubokaOJ, et al. (2016) Functional recovery in major depressive disorder: focus on early optimized treatment. Prim Care Companion CNS Disord18.
26.
HamiltonM (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry23: 56–62.
27.
HirschfeldRMDunnerDLKeitnerG, et al. (2002) Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Biol Psychiatry51: 123–133.
28.
IwataNTourianKAHwangE, et al. (2013) Efficacy and safety of desvenlafaxine 25 and 50 mg/day in a randomized, placebo-controlled study of depressed outpatients. J Psychiatr Pract19: 5–14.
29.
KatzMMMeyersALPrakashA, et al. (2009) Early symptom change prediction of remission in depression treatment. Psychopharmacol Bull42: 94–107.
30.
KennedySHLamRWMcIntyreRS, et al. (2016) Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. Can J Psychiatry61: 540–560.
31.
KornsteinSGMcIntyreRSThaseME, et al. (2014) Desvenlafaxine for the treatment of major depressive disorder. Expert Opin Pharmacother15: 1449–1463.
32.
LamRW (2012) Onset, time course and trajectories of improvement with antidepressants. Eur Neuropsychopharmacol12: S492–S498.
33.
LaoutidisZGKioulosKT (2015) Desvenlafaxine for the acute treatment of depression: a systematic review and meta-analysis. Pharmacopsychiatry48: 187–199.
34.
LiebowitzMRManleyALPadmanabhanSK, et al. (2008) Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin24: 1877–1890.
35.
LiebowitzMRTourianKAHwangE, et al. (2013) A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/d in adult outpatients with major depressive disorder. BMC Psychiatry13: 94.
36.
MachadoMIskedjianMRuizI, et al. (2006) Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin22: 1825–1837.
37.
Machado-VieiraRBaumannJWheeler-CastilloC, et al. (2010) The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments. Pharmaceuticals (Basel)3: 19–41.
38.
McIntyreRS (2013) Using measurement strategies to identify and monitor residual symptoms. J Clin Psychiatry74(Suppl 2): 14–18.
39.
McIntyreRSGommollCChenC, et al. (2016) The efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trials. CNS Spectr21: 385–392.
40.
McIntyreRSLeeYMansurRB (2015) Treating to target in major depressive disorder: response to remission to functional recovery. CNS Spectr20: 20–30; quiz 31.
41.
MacQueenGFrodlT (2011) The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research?Mol Psychiatry16: 252–264.
42.
MaierWPhilippM (1985) Improving the assessment of severity of depressive states: a reduction of the Hamilton Depression Scale. Pharmacopsychiatry18: 114–115.
43.
MallinckrodtCHPrakashAHoustonJP, et al. (2007) Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). Neuropsychobiology56: 73–85.
44.
ManeetonNManeetonBEurviriyanukulK, et al. (2013) Efficacy, tolerability, and acceptability of bupropion for major depressive disorder: a meta-analysis of randomized-controlled trials comparison with venlafaxine. Drug Des Devel Ther7: 1053–1062.
45.
MitchellHAWeinshenkerD (2010) Good night and good luck: norepinephrine in sleep pharmacology. Biochem Pharmacol79: 801–809.
46.
MontgomerySAÅsbergM (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry134: 382–389.
47.
National Institute of Mental Health (2015) Strategic Plan for Research. Bethesda, MD: National Institute of Mental Health.
48.
OlubokaOJKatzmanMAHabertJ, et al. (2018) Functional recovery in major depressive disorder: providing early optimal treatment for the individual patient. Int J Neuropsychopharmacol21: 128–144.
49.
PompiliMVenturiniPPalermoM, et al. (2013) Mood disorders medications: predictors of nonadherence – review of the current literature. Expert Rev Neurother13: 809–825.
50.
Pristiq [package insert] (2018). Philadelphia, PA: Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer Inc.
51.
RedrobeJPBourinMColombelMC, et al. (1998) Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology138: 1–8.
52.
SchachtAGorwoodPBoyceP, et al. (2014) Depression symptom clusters and their predictive value for treatment outcomes: results from an individual patient data meta-analysis of duloxetine trials. J Psychiatr Res53: 54–61.
53.
SheehanDV (2000) Sheehan disability scale. In: RushAJPincusHAFirstMB (eds) Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association, 113–115.
54.
SheehanDVHarnett-SheehanKSpannME, et al. (2011) Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale. Int Clin Psychopharmacol26: 75–83.
55.
SheltonRCPrakashAMallinckrodtCH, et al. (2007) Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. Int J Clin Pract61: 1337–1348.
56.
SoaresCNEndicottJBoucherM, et al. (2014a) Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder. CNS Spectr19: 519–527.
57.
SoaresCNFayyadRSGuico-PabiaCJ (2014b) Early improvement in depressive symptoms with desvenlafaxine 50 mg/d as a predictor of treatment success in patients with major depressive disorder. J Clin Psychopharmacol34: 57–65.
58.
StahlSM (1998) Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. J Clin Psychiatry59: 23–29.
59.
StahlSM (2003) Deconstructing psychiatric disorders, part 2: An emerging, neurobiologically based therapeutic strategy for the modern psychopharmacologist. J Clin Psychiatry64: 1145–1146.
60.
StahlSMZhangLDamatarcaC, et al. (2003) Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J Clin Psychiatry64: 6–17.
61.
SuzukiAAoshimaTFukasawaT, et al. (2005) A three-factor model of the MADRS in major depressive disorder. Depress Anxiety21: 95–97.
62.
ThaseMAsamiYWajsbrotD, et al. (2017) A meta-analysis of the efficacy of venlafaxine extended release 75–225 mg/day for the treatment of major depressive disorder. Curr Med Res Opin33: 317–326.
63.
ThaseMEKornsteinSGGermainJM, et al. (2009) An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr14: 144–154.
64.
TourianKAPadmanabhanSKGroarkJ, et al. (2009) Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther31: 1405–1423.
65.
WainwrightSRGaleaLA. (2013) The neural plasticity theory of depression: assessing the roles of adult neurogenesis and PSA-NCAM within the hippocampus. Neural Plasticity2013: 805497.
66.
World Health Organization (2017) Depression and Other Common Mental Disorders: Global Health Estimates. Geneva, Switzerland: World Health Organization.
67.
ZimmermanMPosternakMAChelminskiI (2004) Derivation of a definition of remission on the Montgomery–Åsberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. J Psychiatr Res38: 577–582.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
